| Theme |
Present status of lymphoid proliferative disease of the colo-rectum with special reference to malignant lymphoma |
| Title |
Treatment of primary malignant lymphoma of large intestine |
| Author |
Yasuo Kakugawa |
Department of Gastrointestinal Endoscopy, National Cancer Center Hospital |
| Author |
Takahiro Kozu |
Department of Gastrointestinal Endoscopy, National Cancer Center Hospital |
| Author |
Masahiro Kami |
Department of Hematopoietic Stem-Cell Transplantation, National Cancer Center Hospital |
| Author |
Takahisa Matsuda |
Department of Gastrointestinal Endoscopy, National Cancer Center Hospital |
| Author |
Yutaka Saito |
Department of Gastrointestinal Endoscopy, National Cancer Center Hospital |
| Author |
Takahiro Fujii |
Takahiro Fujii Clinic |
| [ Summary ] |
Treatment of primary malignant lymphoma of the large intestine may be performed in various ways. Surgical treatment with chemotherapy is usually performed for primary malignant lymphoma of the large intestine. CHOP chemotherapy is the standard treatment for non-Hodgkin's lymphoma. The addition of rituximab to the CHOP regimen has become popular. Radiotherapy is also effective for malignant lymphoma and is usually performed for inoperable lesions. H. pylori eradication therapy is reported to induce regression of low grade MALT lymphoma of the large intestine. Hematopoietic stem cell transplantation is also performed for malignant lymphoma. Primary malignant lymphoma of the large intestine is very rare, therefore a standard treatment has not been established yet. It is therefore important for gastroenterologists, hematologists and radiologists to discuss treatment option for primary malignant lymphoma of the large intestine. |